<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To examine whether the dosage of a platelet-suppressive agent at which an antithrombotic effect is adequate and <z:hpo ids='HP_0001892'>bleeding tendency</z:hpo> is not increased can be found, the antithrombotic effects, antiplatelet effects and <z:mp ids='MP_0001914'>bleeding</z:mp> times of <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> and aspirin were investigated in the rat experimental <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation model </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">Thrombus</z:e> formation was determined by measuring the change in wet weight of a silk thread placed in a carotid arteriovenous shunt </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="9588">Ticlopidine</z:chebi> inhibited <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation and platelet aggregation at rather low doses (50-100 mg/kg) without prolonging <z:mp ids='MP_0001914'>bleeding</z:mp> time </plain></SENT>
<SENT sid="3" pm="."><plain>However, aspirin did not inhibit <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation at even the highest examined dose (200 mg/kg), while <z:mp ids='MP_0001914'>bleeding</z:mp> time was prolonged at even the lowest dose (50 mg/kg) </plain></SENT>
<SENT sid="4" pm="."><plain>These results suggest that a dosage of antithrombotic agent that does not increase <z:hpo ids='HP_0001892'>bleeding tendency</z:hpo> can be easily established using <z:chebi fb="0" ids="9588">ticlopidine</z:chebi>, although it is relatively difficult using aspirin </plain></SENT>
</text></document>